Literature DB >> 24956971

Should thiazide diuretics be given as first line antihypertensive therapy or in addition to other medications?

Valentina Trimarco1, Raffaele Izzo, Teresa Migliore, Francesco Rozza, Marina Marino, Maria Virginia Manzi, Marina De Marco, Giovanni de Simone, Nicola De Luca.   

Abstract

INTRODUCTION: The recommendation to start antihypertensive therapy with diuretics (D) might produce delay in blood pressure (BP) control and, possibly, increase cost/benefit ratio. AIM: We evaluate the effects of D in relation to the administration of other anti-hypertensive medications, in clinical practice.
METHODS: General practitioners recruited 2,409 hypertensive patients with indication to antihypertensive therapy, who were randomized to start treatment with chlorthalidone (12.5-25  mg daily, group D) or any other single medications (excluding thiazides, group A). The patients have been followed for at least 2 years. RESULT: Among the 2,409 patients recruited (42.5 % women), 1,205 were randomized in group D and 1,204 in group A, of which 1,051 (or 87 %) and 1026 (or 85 %) respectively, completed the study. The number of patients in optimal BP control was similar in the two groups (65.0 vs 64.0 %; p = NS). During follow-up, the group D had prescribed a slightly greater number of medications compared to the group A who added D as second line (2.3 vs 2.1; p < 0.0001). In particular group D took more β-blockers (27.1 vs 14.9 %; p < 0.0001) with a similar number of patients in optimal BP control (64.35 vs 63.9 %; p = NS).
CONCLUSION: The beginning of antihypertensive therapy with diuretics is more often subject to the addition of one or more medications to obtain an effective blood pressure control, since the diuretic administered at the beginning of the antihypertensive regimen is only rarely associated with optimal blood pressure control.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24956971     DOI: 10.1007/s40292-014-0065-0

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  22 in total

1.  Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data.

Authors:  J J Caro; J L Speckman; M Salas; G Raggio; J D Jackson
Journal:  CMAJ       Date:  1999-01-12       Impact factor: 8.262

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.

Authors:  William J Elliott; Peter M Meyer
Journal:  Lancet       Date:  2007-01-20       Impact factor: 79.321

4.  Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.

Authors:  Pierre Boutouyrie; Assya Achouba; Patrick Trunet; Stéphane Laurent
Journal:  Hypertension       Date:  2010-04-19       Impact factor: 10.190

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial.

Authors:  G Greenberg; P J Brennan; W E Miall
Journal:  Am J Med       Date:  1984-02-27       Impact factor: 4.965

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Hypertensive target organ damage predicts incident diabetes mellitus.

Authors:  Raffaele Izzo; Giovanni de Simone; Valentina Trimarco; Eva Gerdts; Renata Giudice; Olga Vaccaro; Nicola De Luca; Bruno Trimarco
Journal:  Eur Heart J       Date:  2013-07-23       Impact factor: 29.983

9.  Insufficient control of blood pressure and incident diabetes.

Authors:  Raffaele Izzo; Giovanni de Simone; Marcello Chinali; Guido Iaccarino; Valentina Trimarco; Francesco Rozza; Renata Giudice; Bruno Trimarco; Nicola De Luca
Journal:  Diabetes Care       Date:  2009-02-17       Impact factor: 19.112

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.